Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Deferred Revenue (2022 - 2025)

Crinetics Pharmaceuticals has reported Current Deferred Revenue over the past 4 years, most recently at $1.2 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 43.24% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 43.24%, while the annual FY2025 figure was $1.2 million, 43.24% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $1.2 million at Crinetics Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $9.4 million in Q2 2022 and troughed at $1.2 million in Q4 2025.
  • A 4-year average of $4.6 million and a median of $2.6 million in 2022 define the central range for Current Deferred Revenue.
  • On a YoY basis, Current Deferred Revenue climbed as much as 185.88% in 2023 and fell as far as 75.35% in 2023.
  • Year by year, Current Deferred Revenue stood at $8.3 million in 2022, then tumbled by 75.35% to $2.1 million in 2023, then rose by 5.84% to $2.2 million in 2024, then tumbled by 43.24% to $1.2 million in 2025.
  • Business Quant data shows Current Deferred Revenue for CRNX at $1.2 million in Q4 2025, $1.6 million in Q3 2025, and $1.9 million in Q2 2025.